1.Nonalcoholic steatohepatitis: Pathogenesis and treatment.
The Korean Journal of Hepatology 2008;14(1):12-27
Nonalcoholic fatty liver disease (NAFLD) is characterized by a wide spectrum of liver damage spanning steatosis, nonalcoholic steatohepatitis (NASH), cryptogenic liver cirrhosis, and even to hepatocellular carcinoma. Investigations in the last few years have focused on NASH, a relatively aggressive form of liver disease, due largely to the explosion of information provided by clinical and basic science studies related to the widespread presence of risk factors, such as obesity, type II diabetes mellitus, and dyslipidemia. This is especially important given that obesity and type II diabetes mellitus have recently reached epidemic proportions in Korea. The pathogenesis of NASH is multifactorial, with insulin resistance and increased fatty acid possibly being important factors in the accumulation of hepatocellular fat, and oxidant stress, lipid peroxidation, mitochondrial dysfunction, and dysregulation of variable cytokines possibly being important causes of hepatocellular injury in steatotic liver. Because not all steatotic livers progress to NASH, some other environmental factors or a combination of genetic factors are thought to be required for progression to NASH and fibrosis. Lifestyle modifications continue to be the cornerstone therapy in NAFLD, but some insulin-sensitizing drugs might be more effective in treating NASH. Many pilot trials for antioxidants and lipid-lowering and hepatic protective agents have yielded promising initial results in improving liver enzymes or features of liver histology. However, the efficacy of these agents remains questionable. Despite recent gains in understanding NASH, several issues related to its natural history, pathogenesis, and treatment remain unresolved.
Adipose Tissue/metabolism
;
Antilipemic Agents/therapeutic use
;
Antioxidants/therapeutic use
;
Fatty Liver/*etiology/*therapy
;
Hepatitis/*etiology/therapy
;
Humans
;
Insulin Resistance
;
Life Style
;
Lipid Peroxidation
;
Mitochondria/metabolism
;
Obesity/diet therapy/etiology
;
Oxidative Stress
;
Risk Factors
2.A Case of Hypothyroidism and Type 2 Diabetes Associated with Type V Hyperlipoproteinemia and Eruptive Xanthomas.
Jeong Rang PARK ; Tae Sik JUNG ; Jung Hwa JUNG ; Gyeong Won LEE ; Me Ae KIM ; Ki Jong PARK ; Deok Ryong KIM ; Se Ho CHANG ; Soon Il CHUNG ; Jong Ryeal HAHM
Journal of Korean Medical Science 2005;20(3):502-505
Primary hypothyroidism and type 2 diabetes are both typically associated with the increased level of triglycerides. To date, there have been only a few case reports of type 2 diabetes patients with both type V hyperlipoproteinemia and eruptive xanthomas, but there have been no reports of hypothyroidism patients associated with eruptive xanthomas. We report here on a case of a 48-yr old female patient who was diagnosed with type 2 diabetes and primary hypothyroidism associated with both type V hyperlipoproteinemia and eruptive xanthomas. We found rouleaux formation of RBCs in peripheral blood smear, elevated TSH, and low free T4 level, and dyslipidemia (total cholesterol 18.1 mM/L, triglyceride 61.64 mM/L, HDL 3.0 mM/L, and LDL 2.54 mM/L). She has taken fenofibrate, levothyroxine, and oral hypoglycemic agent for 4 months. After treatment, both TSH level and lipid concentration returned to normal range, and her yellowish skin nodules have also disappeared.
Antilipemic Agents/therapeutic use
;
Diabetes Mellitus, Type 2/blood/*complications/drug therapy
;
Erythrocyte Aggregation
;
Female
;
Humans
;
Hyperlipidemia/blood
;
Hyperlipoproteinemia Type V/blood/*complications/drug therapy
;
Hypoglycemic Agents/therapeutic use
;
Hypothyroidism/blood/*complications/drug therapy
;
Middle Aged
;
Procetofen/therapeutic use
;
Research Support, Non-U.S. Gov't
;
Skin Diseases/blood/complications/drug therapy
;
Thyrotropin/blood/therapeutic use
;
Thyroxine/blood
;
Treatment Outcome
;
Xanthomatosis/blood/*complications/drug therapy